**BACIL Pharma Limited** is an Indian healthcare solutions provider currently undergoing a profound strategic transformation. Historically focused on pharmaceutical formulations, the company has recently pivoted toward a diversified holding and investment model. This transition is marked by aggressive capital expansion, strategic equity acquisitions in the logistics and commodities sectors, and a comprehensive restructuring of corporate governance to facilitate a new growth phase. --- ### **Core Pharmaceutical Portfolio and Operational Status** While the company maintains its identity as a healthcare provider, its core industrial operations are currently in a state of evaluation and transition. * **Product Capabilities:** The company is equipped for the development, manufacturing, and distribution of diverse delivery formats, including: * **Oral Solids:** Tablets and Capsules. * **Injectables:** Liquid and Lyophilized formats. * **Topicals:** Ointments. * **Specialty Products:** Tailored for specific therapeutic segments. * **Operational Reality:** As of **FY 2024-25**, the company reported **zero operational income** from these core activities for the second consecutive year. Management is currently adopting a conservative approach, seeking to bridge the gap between healthcare needs and accessible medicines through a more sustainable operational model in the future. * **Segment Reporting:** Under **Ind AS 108**, the company operates as a single reportable segment; there are currently no separate geographical or product segments identified. --- ### **Strategic Pivot: The CNX Corporation Acquisition** The defining element of the company’s current strategy is its inorganic growth through a significant stake in **CNX Corporation Limited (CCL)**. This move is intended to leverage synergies in the **Commodities Industry, Logistics, and Supply Chain Management**. * **Ownership Stake:** The company has acquired a **29.81%** stake in **CCL** (with a target of **30.75%**), officially designating it as an **Associate Company**. * **Transaction Structure:** The acquisition was executed via a **Share Swap** (consideration other than cash). Bacil Pharma issued **8,290,500 equity shares** at a price of **₹32 per share** to the shareholders of CCL. * **Total Purchase Consideration:** Valued at **₹26,52,96,000**. * **Strategic Intent:** By integrating with CCL, Bacil Pharma aims to diversify its revenue streams and utilize the expertise of new board members specialized in large-scale logistics and commodity trading. --- ### **Financial Performance and Turnaround Metrics** Despite the lack of core manufacturing revenue, the company achieved a financial turnaround in **FY 2024-25**, moving from a loss-making position to profitability through non-operational streams. | Particulars (Standalone) | FY 2024-25 (₹ in Lakhs) | FY 2023-24 (₹ in Lakhs) | Y-o-Y Change | | :--- | :---: | :---: | :---: | | **Operational Income** | **0.00** | **0.00** | **-** | | **Other Income** | **66.14** | **13.05** | **+406.8%** | | **Total Expenses** | **25.39** | **18.95** | **+33.9%** | | **Profit Before Tax (PBT)** | **40.76** | **(5.90)** | **Turnaround** | | **Profit After Tax (PAT)** | **40.05** | **11.38** | **+251.9%** | | **Earnings Per Share (EPS)** | **0.69** | **(0.10)** | **Turnaround** | * **Profitability Drivers:** The return to profitability is attributed to a surge in **Other Income** and the implementation of **Prudent Cost Control Measures**. * **Solvency:** The company has **not defaulted** on any dues to financial institutions and has not been classified as a willful defaulter. --- ### **Capital Structure and Fundraising Strategy** To support its expansion and the CCL acquisition, the company has significantly scaled its authorized and paid-up capital. * **Authorized Share Capital:** Increased from **₹8 Crore** to **₹20 Crore** (divided into **2 Crore** equity shares of **₹10** each). * **Total Voting Capital:** As of **February 2026**, the equity base consists of **14,353,000** fully paid-up shares. * **Preferential Allotment (Cash):** The company raised **₹5,00,00,000** by issuing **15,62,500** equity shares to non-promoters at **₹32** per share to fund working capital and growth. * **Enhanced Borrowing Powers:** Shareholders approved borrowing limits up to **₹50 Crore** under Section 180(1)(c). * **Debt-to-Equity Conversion:** An enabling provision allows for the conversion of loans (up to **₹50 Crore**) into equity shares at the lender's option or in the event of default. --- ### **Corporate Governance and Management Restructuring** The company has undergone a major leadership overhaul to align with its new diversified business model. * **Board Appointments:** **Mr. Mehul Hasmukhbhai Shah** was appointed as **Executive Director** in August 2024 for a **5-year term**. A new **Chief Financial Officer (CFO)** was also appointed in **July 2025**. * **Promoter Re-classification:** In **September 2025**, the company initiated the re-classification of "Outgoing Promoters" to the **Public Category**. These individuals now hold less than **10%** voting rights and are restricted from KMP roles for **3 years**. * **Recent Shareholding Shifts:** In **February 2026**, an off-market transaction saw a specific acquirer group increase their stake from **14.46%** to **16.60%** (**2,381,695 shares**). --- ### **Risk Profile and Auditor Concerns** Investors should note several critical risks and transparency issues highlighted in recent statutory audits. * **Internal Control Deficiencies:** Auditors have noted the absence of an adequate **internal financial control system** over financial reporting, raising the risk of material misstatements. * **Verification of Fund Usage:** There is a lack of documentation regarding the **end use of funds** raised through preferential allotments. * **Asset Recoverability:** Significant uncertainty exists regarding the recoverability of **loans, advances, and deposits** extended to third parties, as management has not provided necessary confirmations. * **Statutory Non-compliance:** The company has faced delays in filing **GST returns and TDS statements**, which may lead to unprovided interest and penalties. * **Related Party Transactions:** Auditors were unable to confirm if all transactions were conducted at **arm’s length** due to incomplete information. * **Operational Viability:** While the company is currently solvent (current assets exceed current liabilities), the **sustained lack of core revenue** poses a long-term risk to business viability. | Risk Category | Key Concern | | :--- | :--- | | **Governance** | Lack of transparency in fund utilization and related party dealings. | | **Compliance** | Delays in statutory tax filings (GST/TDS). | | **Operational** | Total reliance on non-core income; zero manufacturing revenue. | | **Financial** | Uncertainty over the recoverability of substantial loans and advances. |